相似文献
1
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.
J Clin Microbiol. 2010 Jul;48(7):2613-4. doi: 10.1128/JCM.00806-10. Epub 2010 May 26.
2
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
J Clin Microbiol. 2005 Nov;43(11):5425-7. doi: 10.1128/JCM.43.11.5425-5427.2005.
3
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
J Clin Microbiol. 2008 Jan;46(1):150-6. doi: 10.1128/JCM.01901-07. Epub 2007 Nov 21.
4
Rezafungin Activity against Contemporary Nordic Clinical Isolates and Determined by the EUCAST Reference Method.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02438-19.
5
EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00659-19. Print 2019 Sep.
6
In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.
Diagn Microbiol Infect Dis. 2017 Nov;89(3):205-211. doi: 10.1016/j.diagmicrobio.2017.07.007. Epub 2017 Jul 21.
7
In vitro activity of anidulafungin against Candida albicans biofilms.
Antimicrob Agents Chemother. 2008 Jun;52(6):2242-3. doi: 10.1128/AAC.00211-08. Epub 2008 Apr 7.
8
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
9
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00238-18. Print 2018 Jun.
10
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02045-16. Print 2017 Mar.
引用本文的文献
1
Elevated chitin content reduces the susceptibility of Candida species to caspofungin.
Antimicrob Agents Chemother. 2013 Jan;57(1):146-54. doi: 10.1128/AAC.01486-12. Epub 2012 Oct 22.
本文引用的文献
1
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
J Clin Microbiol. 2010 Jan;48(1):52-6. doi: 10.1128/JCM.01590-09. Epub 2009 Nov 18.
2
Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).
J Clin Microbiol. 2009 Jun;47(6):1942-6. doi: 10.1128/JCM.02434-08. Epub 2009 Apr 22.
3
Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.
Antimicrob Agents Chemother. 2009 Aug;53(8):3347-52. doi: 10.1128/AAC.01480-08. Epub 2009 Apr 13.
4
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
J Clin Microbiol. 2008 Aug;46(8):2620-9. doi: 10.1128/JCM.00566-08. Epub 2008 Jun 25.
5
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. doi: 10.1128/AAC.01061-07. Epub 2007 Dec 10.
6
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
J Clin Microbiol. 2008 Jan;46(1):150-6. doi: 10.1128/JCM.01901-07. Epub 2007 Nov 21.
7
Initial results from a longitudinal international surveillance programme for anidulafungin (2003).
J Antimicrob Chemother. 2004 Dec;54(6):1051-6. doi: 10.1093/jac/dkh504. Epub 2004 Nov 25.
8
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Clin Infect Dis. 2004 Sep 15;39(6):770-5. doi: 10.1086/423378. Epub 2004 Aug 27.
9
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.
Antimicrob Agents Chemother. 2003 Oct;47(10):3149-54. doi: 10.1128/AAC.47.10.3149-3154.2003.
10
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Antimicrob Agents Chemother. 2003 Mar;47(3):1068-71. doi: 10.1128/AAC.47.3.1068-1071.2003.
Zotero 插件